Every 10-Q that Biofrontera Inc. Warrants (BFRIW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BFRIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BFRIW filings page.
Biofrontera Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Net product revenue rose to $12.0 million for the quarter and $22.1 million year-to-date, up from $9.0 million and $17.6 million in 2025, driven by Ameluz sales. Loss from operations narrowed to $0.5 million for the quarter and $4.8 million for six months, with net loss of $0.6 million and $5.4 million, respectively.
Cash used in operations improved to $1.7 million in the first half versus $7.2 million a year earlier, but cash and equivalents declined to $4.7 million, and accumulated deficit reached $133.3 million. Management states that current capital resources are not adequate for 12 months and explicitly discloses substantial doubt about the company’s ability to continue as a going concern, absent new financing or milestone receipts.
Leverage includes $4.6 million of senior secured convertible notes and $0.5 million of warrant liabilities, with significant potential dilution from preferred stock, warrants, options and notes. The October 2025 strategic acquisition of U.S. rights to Ameluz and RhodoLED shifted costs from transfer pricing to a sales-based earnout, resulting in $2.6 million earnout expense in the first half. In May 2026, a U.S. International Trade Commission order prohibited import and sale of RhodoLED XL and Ameluz for use with that device; Biofrontera recorded $0.5 million of remediation cost and a related $0.1 million inventory write-down.
Biofrontera Inc. reported first‑quarter 2026 net product revenue of $10.1M, up 17.4% from the prior year, driven mainly by higher Ameluz unit volumes and a late‑2025 price increase. Despite this growth, the company recorded a net loss of $4.8M, slightly larger than in 2025.
Cash and cash equivalents were $6.3M as of March 31, 2026, with operating cash outflows of about $0.1M in the quarter. Management states that existing capital resources are not adequate for twelve months and discloses substantial doubt about continuing as a going concern without additional financing or improved profitability.
The quarter also reflects a new cost structure from the 2025 strategic transaction with the Biofrontera Group, which replaced a 25% transfer‑pricing model with a lower earnout tied to Ameluz sales. Separately, an International Trade Commission final determination on RhodoLED XL led to a $0.5M remediation charge and restrictions on importing and selling certain lamp components, though the company has appealed elements of the patent dispute and the orders are under Presidential Review.
Biofrontera Inc. reported second-quarter product revenue of $9.03 million, up from $7.83 million a year earlier, with total six-month revenue of $17.62 million. The company recorded a net loss of $5.32 million for the quarter and $9.53 million for the six months, while cash and cash equivalents totaled $7.24 million at June 30, 2025 versus $5.91 million at year-end. Accumulated deficit was $126.9 million and warrant liabilities decreased to $0.55 million from $1.25 million, producing non-cash fair value gains recognized in results.
The company signed a binding Term Sheet to acquire U.S. rights to Ameluz and RhodoLED, agreeing to royalty payments of 12% (or 15% if U.S. Ameluz revenue exceeds $65.0 million) and to issue Series D preferred shares to the seller. Biofrontera recorded an $8.5 million advance for Series C preferred stock and disclosed substantial doubt about its ability to continue as a going concern. The report also discloses Nasdaq noncompliance notices for minimum bid price and stockholders' equity and ongoing patent and marketing litigation that could be material.